title: Seronegative myasthenia gravis: disease severity and prognosis.
abstract: Around 10-20% of myasthenia gravis (MG) patients do not have acetylcholine receptor (AChR) antibodies (seronegative), of whom some have antibodies to a membrane-linked muscle specific kinase (MuSK). To examine MG severity and long-term prognosis in seronegative MG compared with seropositive MG, and to look specifically at anti-AChR antibody negative and anti-MuSK antibody negative patients. Seventeen consecutive seronegative non-thymomatous MG patients and 34 age and sex matched contemporary seropositive non-thymomatous MG controls were included in a retrospective follow-up study for a total period of 40 years. Clinical criteria were assessed each year, and muscle antibodies were assayed. There was no difference in MG severity between seronegative and seropositive MG. However, when thymectomized patients were excluded from the study at the year of thymectomy, seropositive MG patients had more severe course than seronegative (P < 0.001). One seropositive patient died from MG related respiratory insufficiency. The need for thymectomy in seronegative MG was lower than in seropositive MG. None of the seronegative patients had MuSK antibodies. This study shows that the presence of AChR antibodies in MG patients correlates with a more severe MG. With proper treatment, especially early thymectomy for seropositive MG, the outcome and long-term prognosis is good in patients with and without AChR antibodies.
authors.affiliation: Department of Neurology, Haukeland University Hospital, Bergen, Norway. frederik.romi@haukeland.no
authors.forename: F
authors.initials: F
authors.lastname: Romi
authors.forename: J A
authors.initials: JA
authors.lastname: Aarli
authors.forename: N E
authors.initials: NE
authors.lastname: Gilhus
mesh_terms: D000906:Antibodies / Q000378:metabolism*; D001379:Azathioprine / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000276:immunology* / Q000503:physiopathology / Q000601:surgery; D011379:Prognosis; D011863:Radioimmunoassay / Q000379:methods; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology*; D011950:Receptors, Cholinergic / Q000276:immunology*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013934:Thymectomy / Q000379:methods; D013997:Time Factors
chemical_list: D000906:Antibodies; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases; D001379:Azathioprine